AZD0156: A Selective ATM Kinase Inhibitor Empowering Cancer Research

Principle Overview: ATM Kinase Inhibition for DNA Damage Response and Metabolic Modulation

The ataxia telangiectasia mutated (ATM) kinase is a central regulator of the DNA damage response (DDR), orchestrating the detection and repair of DNA double-strand breaks (DSBs), checkpoint control, and maintenance of genomic stability. Dysregulation of ATM signaling is implicated in tumorigenesis, therapeutic resistance, and altered cellular metabolism. AZD0156 (CAS: 1821428-35-6) is a next-generation, potent, and selective ATM kinase inhibitor designed specifically for cancer research. Its sub-nanomolar cellular potency and >1,000-fold selectivity versus other PIKK family members (e.g., ATR, DNA-PKcs) enable researchers to interrogate ATM-specific biology with exceptional precision.

Recent studies, such as Huang et al., 2023, have highlighted ATM’s unexpected role in regulating cancer cell metabolism—specifically, the induction of macropinocytosis in nutrient-poor environments upon ATM inhibition. This dual involvement in DNA double-strand break repair and metabolic adaptation makes AZD0156 uniquely suited for exploring the interplay between genomic stability and metabolic plasticity in cancer therapy research.

Step-by-Step Experimental Workflow with AZD0156

1. Compound Preparation and Storage

• Reconstitution: Dissolve AZD0156 in DMSO at concentrations up to 23.1 mg/mL with gentle warming (37°C). For lower solubility, ethanol (≥5.49 mg/mL) may be used, but water is unsuitable due to insolubility.
• Aliquoting: Prepare small working aliquots to avoid repeated freeze-thaw cycles and minimize compound degradation.
• Storage: Store solid at -20°C. Solutions should be freshly prepared and used promptly, as long-term solution stability is not guaranteed.
• Quality Control: Each batch is supplied with HPLC and NMR purity data (typically >98%).

2. Experimental Setup: Cell-Based Assays

• Cell Line Selection: Choose cancer cell lines with characterized ATM status (WT, mutant, or null) to dissect ATM-specific effects.
• Dose Range Finding: Start with 10 nM–1 μM AZD0156 for dose-response; previous studies report robust ATM inhibition at low nanomolar concentrations.
• Combination Treatments: For DDR studies, co-treat with DNA-damaging agents (e.g., ionizing radiation, etoposide) to assess synergy in DSB repair inhibition. For metabolic studies, include macropinocytosis inhibitors or amino acid supplementation as in the reference study (Huang et al., 2023).
• Endpoint Readouts: Quantify ATM pathway inhibition via phospho-ATM (Ser1981) and downstream targets (e.g., CHK2, γ-H2AX) by Western blot or immunofluorescence. For metabolic adaptation, measure macropinocytosis using FITC-dextran uptake and assess nutrient uptake via metabolomics or isotope tracing.

3. In Vivo Workflow Enhancements

• Formulation: AZD0156 can be formulated for oral administration in preclinical models. Use vehicle controls and monitor for compound stability during dosing.
• Efficacy Assessment: Combine AZD0156 with DNA-damaging chemotherapies or metabolic inhibitors; monitor tumor volume and survival endpoints.
• Pharmacodynamic Biomarkers: Collect tumor and plasma samples for ATM pathway target engagement and metabolite profiling.

Advanced Applications and Comparative Advantages

Unlocking Metabolic Vulnerabilities via ATM Inhibition

AZD0156’s ability to selectively inhibit ATM not only impairs DSB repair but also triggers metabolic adaptations that can be exploited therapeutically. The landmark study by Huang et al. (2023) demonstrated that ATM inhibition drives cancer cells to upregulate macropinocytosis, facilitating nutrient scavenging and survival under metabolic stress. Notably, combined inhibition of ATM and macropinocytosis led to pronounced cell death in vitro and in vivo, revealing a novel synthetic lethality approach for targeting metabolic vulnerabilities in tumors.

Quantitative data from the reference study showed that ATM-inhibited tumors exhibited a significant depletion of branched-chain amino acids (BCAAs) in the tumor microenvironment, highlighting the metabolic reprogramming induced by selective ATM inhibition. Supplementation with BCAAs abrogated macropinocytosis, confirming the metabolic dependency of ATM-inhibited cells.

Comparative Advantages over Other DDR Inhibitors

• Precision: With >1,000-fold selectivity, AZD0156 minimizes off-target effects on related PIKK family kinases (ATR, DNA-PKcs), enabling clearer mechanistic insights into ATM-specific biology.
• Translational Relevance: Oral bioavailability allows for realistic in vivo dosing schedules that mirror clinical trial protocols, supporting seamless bench-to-clinic translation.
• Versatility: Facilitates research in both classical DDR (e.g., γ-H2AX foci formation, cell cycle checkpoint modulation) and metabolic adaptation (e.g., macropinocytosis, amino acid uptake), as shown in both the reference study and recent reviews (AZD0156: Advancing ATM Kinase Inhibition for Metabolic Targeting).

Interlinking with Existing Literature

• Selective ATM Kinase Inhibition with AZD0156: Mechanistic Insights complements this workflow by offering in-depth mechanistic context and highlighting new translational strategies for combining ATM inhibition with metabolic stressors.
• AZD0156: Advanced Perspectives on ATM Kinase Inhibition and Metabolic Vulnerabilities extends the discussion to systems-level analysis, including network-driven vulnerabilities and precision oncology applications.
• AZD0156: Unraveling ATM Inhibition’s Impact on Cancer Cell Metabolism provides a focused review of metabolic reprogramming downstream of ATM inhibition, further supporting the use cases highlighted above.

Troubleshooting and Optimization Tips

• Compound Solubility Issues: If AZD0156 does not fully dissolve in DMSO, gently warm the solution to 37°C and vortex thoroughly. Avoid water as a solvent.
• Cellular Toxicity or Off-Target Effects: Confirm ATM pathway engagement by monitoring phospho-ATM and downstream targets. Use ATM-deficient cell lines as specificity controls.
• Variable Efficacy in Combination Therapies: Optimize dosing sequences—pre-treat with AZD0156 before DNA-damaging agents to maximize synergistic responses. For metabolic studies, titrate amino acid supplementation to directly assess dependency on macropinocytosis.
• Reproducibility in In Vivo Models: Monitor compound stability in dosing vehicles over time. Use appropriate vehicle controls and confirm target engagement in tumor samples post-dosing.
• Data Interpretation: Distinguish between ATM-specific and broader DDR effects by including ATR or DNA-PKcs inhibitors as comparators. Use genetic knockout or rescue models for additional validation.

Future Outlook: Next-Generation Strategies with AZD0156

As a cornerstone selective ATM inhibitor for cancer research, AZD0156 is poised to accelerate discovery in several frontier areas:

• Precision Metabolic Targeting: Exploiting metabolic vulnerabilities (e.g., macropinocytosis dependency) in ATM-deficient or ATM-inhibited tumors for synthetic lethality.
• Checkpoint Control Modulation: Combining AZD0156 with checkpoint inhibitors or PARP inhibitors to potentiate antitumor efficacy, particularly in DDR-deficient backgrounds.
• Genomic Stability Regulation: Dissecting ATM’s role in chromatin remodeling, replication stress, and non-canonical DDR pathways.
• Clinical Translation: Ongoing early-phase clinical trials are evaluating AZD0156’s safety and efficacy in advanced cancers, paving the way for new therapeutic paradigms in ATM-targeted precision oncology.

To realize the full potential of ATM kinase inhibitors like AZD0156, researchers are encouraged to integrate metabolic, genomic, and therapeutic endpoints in both preclinical and translational models. For reagent details, protocols, and quality control information, visit the AZD0156 product page.